PE-22-28: A Literature Course on a TREK-1-Blocking Peptide

This course walks through the published literature that surrounds PE-22-28, a short peptide discussed in the context of blocking the two-pore domain potassium channel TREK-1 (also written K_2P2.1). Each module summarises what studies reported, then closes with the limits of that evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision. No dosing schedules, protocols or outcome expectations are offered here, and where the verified literature contains no number, no number is given.

Module 1: What PE-22-28 Is and How It Has Been Studied

Class and origin

PE-22-28 belongs to a family of peptide TREK-1 blockers whose parent compound, spadin, was derived from the propeptide released during maturation of sortilin. A 2019 review in Pharmacology & Therapeutics traced the history of TREK-1 blockers as candidate antidepressants with a specific focus on spadin and the shorter analogues developed from it, and framed the concept as an alternative pharmacological entry point to monoamine-based drugs (PMID 30291907). PE-22-28 is named for the segment of that parent sequence it corresponds to, which is why the literature usually treats it as a spadin-derived analogue rather than a structurally novel molecule.

The target, not the peptide, carries most of the evidence

A reader tracing PE-22-28 through PubMed quickly finds that the larger, better-characterised body of work concerns the channel itself. Researchers have shown that TREK-1 subunits can assemble with TREK-2 subunits to form functional heterodimers with their own biophysical signature, which complicates the idea of a single, uniform "TREK-1 channel" as a drug target (PMID 27129242). Other groups have reported potent blockers aimed specifically at TWIK-1/TREK-1 heterodimers and discussed them as potential antidepressant leads (PMID 37454597).

Forms described in the literature

Published work on peptide TREK-1 blockers is laboratory work: channel recordings in heterologous expression systems and native cells, tissue-level assays, and rodent behavioural or electrophysiological experiments. A 2024 paper in the International Journal of Molecular Sciences reported that a peptide isolated from tick material blocked TREK-1, illustrating that peptide blockers of this channel continue to be identified and characterised from natural sources as well as designed by analogue chemistry (PMID 39125945).

Limits of the evidence (Module 1)

• The verified literature summarised here contains no human clinical trial of PE-22-28.
• Characterisation of the channel does not establish that any particular peptide acts on it selectively, at any particular exposure, or in an intact organism.
• Where a paper studied a different TREK-1 blocker, its findings describe that blocker, not PE-22-28.

Module 2: Mechanism as Described in the Literature

What TREK-1 does

TREK-1 is a leak-type potassium channel that responds to mechanical and chemical stimuli and helps set resting membrane potential. Researchers reported that TREK-1 channels regulated pressure sensitivity and calcium signalling in trabecular meshwork cells, linking channel activity to mechanotransduction in an ocular tissue (PMID 30446509). A 2024 study described osmotically sensitive TREK channels in rat articular chondrocytes and examined both their expression and their functional role, again placing the channel family inside mechanical and osmotic signalling (PMID 39063089).

Why blockade is the proposed mechanism

The logic in the antidepressant literature is that reducing potassium leak through TREK-1 depolarises target neurons and raises their excitability. A 2024 study in Experimental Neurology reported that TREK-1 inhibition promoted synaptic plasticity in the prelimbic cortex, providing a circuit-level correlate for that reasoning (PMID 38103709). A 2026 paper in Neuropharmacology went further and reported that TREK-1 channel blockade mediated the antidepressant-like effects of hydroxynorketamine, connecting the channel to a mechanism already under study for a small molecule (PMID 41167417).

Channel state is not fixed

TREK-1 function is modulated by intracellular signalling. Researchers reported that PKC- and PKA-dependent phosphorylation modulated TREK-1 function in naïve and neuropathic rats, meaning the channel a blocker encounters may behave differently depending on the physiological or pathological state of the tissue (PMID 33006141). Subunit composition adds a second layer, since TREK-1 and TREK-2 subunits were shown to form functional heterodimers (PMID 27129242).

Selectivity is an empirical question

Peptides that act on mechanosensitive membrane proteins are not automatically selective. A 2011 Biochemistry report showed that the spider-derived peptide GsMTx4 inhibited the mechanosensitive ion channel Piezo1, a useful reminder that peptide channel modulators are profiled against multiple targets before selectivity claims are made (PMID 21696149).

Limits of the evidence (Module 2)

• Mechanistic plausibility is not efficacy; none of the cited mechanism papers measured a clinical outcome.
• Blockade experiments often use tool compounds, genetic manipulation or other blockers, so the mechanism narrative is about the channel rather than about PE-22-28 specifically.
• Because phosphorylation state and heterodimer composition alter TREK-1 behaviour, results from one preparation may not transfer to another.

Module 3: Reported Outcomes by Study

The table below summarises what each verified paper studied and what it reported. No benefit is implied for any person, and no study listed here tested PE-22-28 in humans.

Limits of the evidence (Module 3)

• The strongest signals in this table are mechanistic and preclinical; behavioural readouts in rodents are described as "antidepressant-like" precisely because they are not clinical diagnoses (PMID 41167417).
• Several entries describe TREK-1 biology in tissues unrelated to mood, such as cartilage and fat, and were not designed to evaluate any peptide therapeutic (PMID 39063089, PMID 40057491).
• No head-to-head comparison of PE-22-28 against an approved antidepressant appears in the verified set.

Module 4: PE-22-28 Side Effects: What Studies Report

The honest summary is that the verified literature reviewed here does not contain a published adverse-event table for PE-22-28. There is no human safety study, no dose-ranging tolerability report and no systematic toxicology paper for this peptide among these references. What the literature does provide is a map of where TREK-1 is expressed and what it appears to do outside the brain, which is the material toxicologists would use to frame theoretical risk.

Off-target tissues identified in the literature

• Cardiac electrophysiology. A 2024 Circulation study reported circulating autoantibodies targeting TREK-1 in patients with short-coupled ventricular fibrillation, associating disturbance of this channel's function with a severe arrhythmia phenotype (PMID 39315453). That paper studied autoantibodies rather than a peptide drug, but it is the clearest published signal that TREK-1 is not a brain-only target.
• Ocular pressure regulation. Researchers reported that TREK-1 channels regulated pressure sensitivity and calcium signalling in trabecular meshwork cells, the tissue that governs aqueous outflow (PMID 30446509).
• Adipose tissue. A 2025 Cell Death & Disease paper reported a novel function for TREK-1 in regulating adipocyte differentiation and lipid accumulation (PMID 40057491).
• Cartilage. Osmotically sensitive TREK channels were reported in rat articular chondrocytes with a described functional role (PMID 39063089).
• Sensory and pain pathways. TREK-1 function was shown to be modulated by PKC- and PKA-dependent phosphorylation in naïve and neuropathic rats (PMID 33006141).

Limits of the evidence (Module 4)

• Absence of published adverse events is not evidence of safety; it reflects that the studies were not safety studies.
• Expression of a target in a tissue does not predict whether a given peptide reaches that tissue or alters its function.
• The cardiac and ocular findings come from autoantibody and cell-physiology work, not from administration of any peptide blocker (PMID 39315453, PMID 30446509).

Module 5: Pharmacokinetics Where Data Exist

No dedicated pharmacokinetic study of PE-22-28 — absorption, distribution, half-life, brain penetration or clearance route — appears among the verified papers used for this course. The 2019 review of TREK-1 blockers discussed the development history of spadin and the analogue strategy built around it, which is the closest the verified set comes to a drug-development discussion of this peptide family (PMID 30291907).

Two structural points from the mechanism literature are relevant to any future PK work. First, TREK-1 is an ion channel embedded in the plasma membrane, so exposure at the target depends on a peptide reaching the relevant tissue compartment rather than simply appearing in plasma; papers characterising TREK-1 in cortical circuits illustrate how far a candidate would need to travel (PMID 38103709). Second, because TREK-1 assembles into heterodimers with other two-pore domain subunits, a pharmacodynamic measure has to specify which channel population was engaged (PMID 27129242, PMID 37454597).

Limits of the evidence (Module 5)

• Without published PK parameters, no statement about duration of action, administration route or accumulation can be supported for PE-22-28.
• In vitro potency figures, where they exist for other blockers, do not translate into systemic exposure estimates.
• Any PK claim encountered elsewhere that is not tied to a peer-reviewed report should be treated as unverified.

Module 6: Regulatory Status, Stated Factually

PE-22-28 is not an approved drug product in the United States or, to the knowledge of the literature summarised here, in other major jurisdictions. There is no marketing authorisation, no approved labelling, no indication and no approved route of administration. Its appearance in commerce is as a laboratory chemical: material labelled research use only (RUO) is designated for in vitro or preclinical laboratory work and is not intended for human or veterinary use, and RUO labelling is not a regulatory finding of safety, purity, potency or identity.

On compounding: in the United States, licensed pharmacies compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act must use bulk drug substances that meet defined statutory criteria, generally an applicable USP or NF monograph, a component of an approved drug, or inclusion on the FDA's bulk drug substances lists. Peptides without those pathways are not eligible bulk substances for compounding. Research peptides with no approved product and no monograph therefore fall outside the compounding framework as a matter of statute rather than of opinion.

The academic literature reflects the same early-stage picture: TREK-1 blockade is discussed as a candidate antidepressant strategy and as a mechanistic hypothesis rather than as an established therapy (PMID 30291907, PMID 37454597). This section is general regulatory information and is not legal advice.

Limits of the evidence (Module 6)

• Regulatory status changes; statutes, bulk substance lists and enforcement priorities are revised over time.
• Status differs by country, and rules for laboratory chemicals differ from rules for medicines.
• Nothing in the research literature confers regulatory standing on a compound.

What the Studies Did Not Test

Reading the verified set end to end, the gaps are as instructive as the findings:

1. No human trials of PE-22-28. Nothing in the verified literature reports efficacy, tolerability or dosing in people.
2. No long-term administration. Chronic-exposure studies with histopathology, cardiac monitoring or metabolic follow-up are absent, despite TREK-1 being implicated in cardiac and adipose biology (PMID 39315453, PMID 40057491).
3. No selectivity panel tied to this peptide. The published caution that peptide modulators can act on other mechanosensitive channels comes from work on a different peptide and a different target (PMID 21696149).
4. No comparison against standard care. Antidepressant-like readouts in rodents were reported for channel blockade, not benchmarked clinically (PMID 41167417, PMID 38103709).
5. No pharmacokinetics. Exposure, half-life and tissue distribution remain undescribed for this peptide.
6. No special-population data. Age, sex, pregnancy, hepatic or renal impairment and drug-interaction questions are untouched, although disease state itself altered TREK-1 regulation in rats (PMID 33006141).

The through-line of this course is that PE-22-28 sits downstream of a genuinely active research field about a mechanosensitive potassium channel, while the peptide itself remains sparsely characterised in the peer-reviewed record. Interested readers can follow the primary sources below rather than relying on summaries.

References

• Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin (Pharmacology & Therapeutics, 2019)
• Tick-Derived Peptide Blocks Potassium Channel TREK-1 (International Journal of Molecular Sciences, 2024)
• Novel potent blockers for TWIK-1/TREK-1 heterodimers as potential antidepressants (Biomedicine & Pharmacotherapy, 2023)
• TREK-1 inhibition promotes synaptic plasticity in the prelimbic cortex (Experimental Neurology, 2024)
• TREK-1 channel blockade mediates the antidepressant-like effects of hydroxynorketamine (Neuropharmacology, 2026)
• PKC- and PKA-dependent phosphorylation modulates TREK-1 function in naïve and neuropathic rats (Journal of Neurochemistry, 2021)
• Formation of Functional Heterodimers by TREK-1 and TREK-2 Two-pore Domain Potassium Channel Subunits (Journal of Biological Chemistry, 2016)
• TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells (Journal of General Physiology, 2018)
• Osmotically Sensitive TREK Channels in Rat Articular Chondrocytes: Expression and Functional Role (International Journal of Molecular Sciences, 2024)
• Novel function of TREK-1 in regulating adipocyte differentiation and lipid accumulation (Cell Death & Disease, 2025)
• Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation (Circulation, 2024)
• The mechanosensitive ion channel Piezo1 is inhibited by the peptide GsMTx4 (Biochemistry, 2011)